Most pre-clinical studies demonstrating the efficacy of GLP-1 agonists in chondroprotection were conducted using animals or cells from animal arthritis models in otherwise healthy, non-obese, young male animals, but not in older or aged or female sex mice or rats, despite the well-recognised differences in molecular pathophysiology compared to younger animals [31]. This evidence concerns the gene GCG and arthritic joint disease.